The most exciting breakthrough is Adaptive Deep Brain Stimulation (aDBS), which reduces Parkinson’s symptoms by up to 50%. While earlier DBS devices gave the brain continuous electrical stimulation, ...

A new Drosophila collection of Parkinsonism models reveals early synaptic cholinergic projection neuron dysfunction, linking synaptic failure to later dopaminergic decline, highlighting a role for ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – ...

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data and AI, presented NeuLogiq® ...

Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater separation with Alzheimer's pTau217 pathology ...

Parkinson's disease is a progressive neurodegenerative disorder, which is characterized by motor symptoms such as tremor, rigidity, slowness of movement and problems with gait. Motor symptoms are ...

A new hypothesis paper appearing in the Journal of Parkinson's Disease on World Parkinson's Day unites the brain- and body-first models with some of the likely causes of the disease ...

Every so often, students and seniors at Rocky Mountain University of Health Professions channel Inigo Montoya by wielding ...

Several lines of evidence link metabolic dysregulation to late-life neurodegenerative diseases. The altered glucose ...

Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells ...

This recent study highlights the neuroprotective potential of TFE3, a transcription factor that plays a pivotal role in counteracting key pathological mechanisms associated with Parkinson's ...